Journal Article

Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation

Katrina A. Morris, John F. Golding, Patrick R. Axon, Shazia Afridi, Claire Blesing, Rosalie E. Ferner, Dorothy Halliday, Raj Jena, Pieter M. Pretorius, D. Gareth Evans, Martin G. McCabe and Allyson Parry

in Neuro-Oncology Practice

Published on behalf of The Society for Neuro-Oncology

Volume 3, issue 4, pages 281-289
Published in print December 2016 | ISSN: 2054-2577
Published online January 2016 | e-ISSN: 2054-2585 | DOI: http://dx.doi.org/10.1093/nop/npv065
Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Palliative Medicine
  • Clinical Oncology
  • Clinical Radiology
  • Neurosurgery

GO

Show Summary Details

Keywords: bevacizumab; neurofibromatosis type 2; schwannoma; vestibular schwannoma

Journal Article.  5571 words.  Illustrated.

Subjects: Medical Oncology ; Palliative Medicine ; Clinical Oncology ; Clinical Radiology ; Neurosurgery

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.